| Original language | English (US) |
|---|---|
| Pages (from-to) | e146-e147 |
| Journal | Journal of Thoracic Oncology |
| Volume | 14 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 2019 |
ASJC Scopus subject areas
- Oncology
- Pulmonary and Respiratory Medicine
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of Thoracic Oncology, Vol. 14, No. 7, 07.2019, p. e146-e147.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Real-World Application of the NAVIGATE Trial
AU - Thiboutot, Jeffrey
AU - Yarmus, Lonny B.
AU - Lee, Hans J.
AU - Rivera, M. Patricia
AU - Ost, David E.
AU - Feller-Kopman, David
N1 - Funding Information: Disclosure: Dr. Yarmus has received grant funding and consulting fees from Veran Medical, Olympus , Boston Scientific and Veracyte. Dr. Lee has received consulting fees from Veracyte and Veran Medical. Dr. Rivera serves as a consultant on the scientific and medical advisory boards of BioAffinity Technologies and Biodesix Technologies. Dr Ost serves on the pulmonary examination committee of the American Board of Internal Medicine and received grant funding from Intuitive Surgical Research during conduct of the study. Dr. Feller-Kopman reports personal fees from Veran Medical during conduct of the study. The remaining author declares no conflict of interest. Funding Information: Disclosure: Dr. Yarmus has received grant funding and consulting fees from Veran Medical, Olympus, Boston Scientific and Veracyte. Dr. Lee has received consulting fees from Veracyte and Veran Medical. Dr. Rivera serves as a consultant on the scientific and medical advisory boards of BioAffinity Technologies and Biodesix Technologies. Dr Ost serves on the pulmonary examination committee of the American Board of Internal Medicine and received grant funding from Intuitive Surgical Research during conduct of the study. Dr. Feller-Kopman reports personal fees from Veran Medical during conduct of the study. The remaining author declares no conflict of interest. Disclosure: Dr. Yarmus has received grant funding and consulting fees from Veran Medical, Olympus, Boston Scientific and Veracyte. Dr. Lee has received consulting fees from Veracyte and Veran Medical. Dr. Rivera serves as a consultant on the scientific and medical advisory boards of BioAffinity Technologies and Biodesix Technologies. Dr Ost serves on the pulmonary examination committee of the American Board of Internal Medicine and received grant funding from Intuitive Surgical Research during conduct of the study. Dr. Feller-Kopman reports personal fees from Veran Medical during conduct of the study. The remaining author declares no conflict of interest.
PY - 2019/7
Y1 - 2019/7
UR - http://www.scopus.com/inward/record.url?scp=85067558771&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067558771&partnerID=8YFLogxK
U2 - 10.1016/j.jtho.2019.02.020
DO - 10.1016/j.jtho.2019.02.020
M3 - Letter
C2 - 31235039
AN - SCOPUS:85067558771
SN - 1556-0864
VL - 14
SP - e146-e147
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - 7
ER -